Implementing MRD in clinical practice for patients with intermediate-risk AML

MRD in AML clinical practiceПодробнее

Treatment of intermediate-risk AML with gemtuzumab ozogamicinПодробнее

The current role of MRD in AML and challenges with implementing this in clinical practiceПодробнее

MRD-guided therapy in patients with intermediate-risk AML compared to unguided cohort using PSMПодробнее

The possibility of using MRD status to drive treatment in AMLПодробнее

The role of allogeneic transplantation in patients with AML in the frontline settingПодробнее

MRD Monitoring in Acute Myeloid LeukemiaПодробнее

The role of MRD monitoring using MFC for AML: a real-world studyПодробнее

When should patients with intermediate-risk AML be indicated for alloSCT?Подробнее

How can MRD guide treatment of AML?Подробнее

MRD in Acute Myeloid LeukemiaПодробнее

The importance of MRD in AML prognosis and therapyПодробнее

MRD in AML: What is it and what do I do about it?Подробнее

The prognostic and therapeutic implications of MRD in AMLПодробнее

Should MRD negativity post remission impact treatment decisions in ELN-intermediate risk AML?Подробнее

Updates on the use of molecular monitoring to detect MRD in AMLПодробнее

Using MRD to guide post-alloSCT treatment decisions in AMLПодробнее

Clinical Cases: MRD in Real-World Clinical PracticeПодробнее

Clinical Use of Molecular MRD Testing in AMLПодробнее